Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma.
Saved in:
| Title: | Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma. |
|---|---|
| Authors: | Pucci P; Department of Pathology, Division of Cellular and Molecular Pathology, University of Cambridge, Cambridge, CB20QQ, UK., Lee LC; Department of Pathology, Division of Cellular and Molecular Pathology, University of Cambridge, Cambridge, CB20QQ, UK.; Merck & Co, 2000 Galloping Hill Rd, Kenilworth, NJ, 07033, USA., Han M; Department of Pathology, Division of Cellular and Molecular Pathology, University of Cambridge, Cambridge, CB20QQ, UK.; OncoSec, San Diego, CA, 92121, USA., Matthews JD; Department of Pathology, Division of Cellular and Molecular Pathology, University of Cambridge, Cambridge, CB20QQ, UK., Jahangiri L; Department of Pathology, Division of Cellular and Molecular Pathology, University of Cambridge, Cambridge, CB20QQ, UK.; Department of Life Sciences, Birmingham City University, Birmingham, UK.; Nottingham Trent University, School of Science & Technology, Clifton Lane, Nottingham, NG11 8NS, UK., Schlederer M; Department of Pathology, Division of Experimental and Translational Pathology, Medical University of Vienna, 1090, Vienna, Austria., Manners E; Department of Pathology, Division of Cellular and Molecular Pathology, University of Cambridge, Cambridge, CB20QQ, UK.; Chelsea and Westminster Hospital, NHS Foundation Trust, London, SW10 9NH, UK., Sorby-Adams A; MRC Mitochondrial Biology Unit, University of Cambridge, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY, UK.; Department of Medicine, University of Cambridge, Addenbrookes Hospital, Hills Road, Cambridge, CB2 0QQ, UK., Kaggie J; Department of Radiology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK., Trigg RM; Department of Pathology, Division of Cellular and Molecular Pathology, University of Cambridge, Cambridge, CB20QQ, UK.; Functional Genomics, GlaxoSmithKline, Stevenage, SG1 2NY, UK., Steel C; Department of Pathology, Division of Cellular and Molecular Pathology, University of Cambridge, Cambridge, CB20QQ, UK., Hare L; Department of Pathology, Division of Cellular and Molecular Pathology, University of Cambridge, Cambridge, CB20QQ, UK.; Department of Paediatric Haematology, Oncology and Palliative Care, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK., James ER; Department of Pathology, Division of Cellular and Molecular Pathology, University of Cambridge, Cambridge, CB20QQ, UK., Prokoph N; Department of Pathology, Division of Cellular and Molecular Pathology, University of Cambridge, Cambridge, CB20QQ, UK., Ducray SP; Department of Pathology, Division of Cellular and Molecular Pathology, University of Cambridge, Cambridge, CB20QQ, UK., Merkel O; Department of Pathology, Medical University of Vienna, Vienna, 1090, Austria.; European Research Initiative for ALK related malignancies (ERIA), Cambridge, CB2 0QQ, UK., Rifatbegovic F; St. Anna Children's Cancer Research Institute, CCRI, Zimmermannplatz 10, 1090, Vienna, Austria., Luo J; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20814, USA., Taschner-Mandl S; St. Anna Children's Cancer Research Institute, CCRI, Zimmermannplatz 10, 1090, Vienna, Austria., Kenner L; Department of Pathology, Medical University of Vienna, Vienna, 1090, Austria.; European Research Initiative for ALK related malignancies (ERIA), Cambridge, CB2 0QQ, UK.; Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, Austria.; Center for Biomarker Research in Medicine (CBmed), Graz, Austria.; Christian Doppler Laboratory for Applied Metabolomics (CDL-AM), Medical University of Vienna, Vienna, Austria., Burke GAA; Department of Paediatric Haematology, Oncology and Palliative Care, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK., Turner SD; Department of Pathology, Division of Cellular and Molecular Pathology, University of Cambridge, Cambridge, CB20QQ, UK. sdt36@cam.ac.uk.; European Research Initiative for ALK related malignancies (ERIA), Cambridge, CB2 0QQ, UK. sdt36@cam.ac.uk.; Faculty of Medicine, Masaryk University, Brno, Czech Republic. sdt36@cam.ac.uk. |
| Source: | Nature communications [Nat Commun] 2024 Apr 23; Vol. 15 (1), pp. 3422. Date of Electronic Publication: 2024 Apr 23. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-024-47771-x |
